SOUTH SAN FRANCISCO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Barbara Leyman, Ph.D., as Chief Business Development Officer, effective July 8, 2024. Dr. Leyman brings 20 years of life science industry business development, investing, and corporate strategy experience to Sutro.
"We are thrilled to welcome Dr. Leyman at a pivotal time for Sutro, as we advance luvelta in two registration-directed trials in both ovarian cancer and a rare pediatric cancer and continue to leverage our proprietary cell-free technology to pioneer the next generation of ADCs," said Bill Newell, Sutro's Chief Executive Officer. "Dr. Leyman brings a strong track record of successful dealmaking, along with a depth of experience in the sector from her time as a life science investor and as a value creator within our industry."
"I am excited to join Sutro and have been impressed by the accomplishments of the Company across its pipeline of clinical, preclinical, and partnership programs," said Dr. Leyman. "This is a testament to the strength of Sutro's capabilities, which I believe offers a completely unique approach to developing ADCs and other therapies that can meaningfully improve patient care. I look forward to working with the Sutro team to continue to build value with luvelta and expand the potential of medicines created by its innovative technology."
Dr. Leyman most recently served as Senior Vice President of Corporate Development at GenEdit, a developer of genetic medicines. Prior to this role, she was a business development leader at Lyell Immunopharma and Calico Life Sciences. Before joining industry, Dr. Leyman was Head of Life Sciences Investment Fund at LRM, a venture capital firm, and worked as Licensing and New Ventures Manager at the Flanders Institute for Biotechnology (VIB). She has served on the board of directors at biopharmaceutical companies Apitope, Complix., and Amakem. Dr. Leyman received a Ph.D. degree in ...